Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis

Yang, Shengnan; Li, Peipei; Jiang, Yale; Wang, Zai; Dai, Huaping; Wang, Chen

doi:10.3389/fcell.2021.639657

Cited by 45 publications

(34 citation statements)

References 124 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the current study, age has become a limiting condition for lung transplantation in IPF patients, and the survival rate after lung transplantation in elderly patients older than 65 years is relatively low ( 108 ). Therefore, it is ofgreat significance to develop effective early diagnostic methods and innovative therapeutic strategies, such as applications of mesenchymal stem cells ( 109 ).…”

Section: Discussionmentioning

confidence: 99%

TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

2021

Int J Mol Med

121

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is a worldwide disease characterized by the chronic and irreversible decline of lung function. Currently, there is no drug to successfully treat the disease except for lung transplantation. Numerous studies have been devoted to the study of the fibrotic process of IPF and findings showed that transforming growth factor-β1 (TGF-β1) plays a central role in the development of IPF. TGF-β1 promotes the fibrotic process of IPF through various signaling pathways, including the Smad, MAPK, and ERK signaling pathways. There are intersections between these signaling pathways, which provide new targets for researchers to study new drugs. In addition, TGF-β1 can affect the fibrosis process of IPF by affecting oxidative stress, epigenetics and other aspects. Most of the processes involved in TGF-β1 promote IPF, but TGF-β1 can also inhibit it. This review discusses the role of TGF-β1 in IPF. Contents1. Introduction 2. TGF-β1-involved pathway in IPF 3. Discussion 4. Conclusion

show abstract

Section: Discussionmentioning

confidence: 99%

TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

2021

Int J Mol Med

121

View full text Add to dashboard Cite

show abstract

“…To complete this section, we focus in lung fibrosis. Many preclinical and clinical studies using MSCs and their secreted compounds have been performed during the last decade for the treatment of interstitial lung diseases [ 142 , 143 , 144 ]. Several studies describe the anti-inflammatory, microbicidal, angiogenic and antifibrotic effects of MSCs in preclinical studies of pulmonary fibrosis, and the treatment with these cells was able to improve lung function and reduce mortality in rodent models of chronic lung diseases [ 145 , 146 , 147 , 148 ].…”

Section: Mscs As a Treatment Of Several Typical Pathologies Regarding Wound Healingmentioning

confidence: 99%

The Role of MSC in Wound Healing, Scarring and Regeneration

Guillamat-Prats

2021

Cells

217

123

View full text Add to dashboard Cite

Tissue repair and regeneration after damage is not completely understood, and current therapies to support this process are limited. The wound healing process is associated with cell migration and proliferation, extracellular matrix remodeling, angiogenesis and re-epithelialization. In normal conditions, a wound will lead to healing, resulting in reparation of the tissue. Several risk factors, chronic inflammation, and some diseases lead to a deficient wound closure, producing a scar that can finish with a pathological fibrosis. Mesenchymal stem/stromal cells (MSCs) are widely used for their regenerative capacity and their possible therapeutically potential. Derived products of MSCs, such as exosomes or extravesicles, have shown a therapeutic potential similar to MSCs, and these cell-free products may be interesting in clinics. MSCs or their derivative products have shown paracrine beneficial effects, regulating inflammation, modifying the fibroblast activation and production of collagen and promoting neovascularization and re-epithelialization. This review describes the effects of MSCs and their derived products in each step of the wound repair process. As well, it reviews the pre-clinical and clinical use of MSCs to benefit in skin wound healing in diabetic associated wounds and in pathophysiological fibrosis.

show abstract

“…Bone marrow-derived MSCs (BMSCs) possess many advantages, including easier culturing, proliferation, isolation and purification, rendering them convenient for clinical application [ 16 , 17 ]. Many researchers have reported on the clinical use of bone marrow-derived MSCs in the treatment of diseases, including cardiac disease [ 18 ], pulmonary disease [ 19 ], and osteoarthritis [ 20 ]. Recent research identified that exosomes derived from BMSCs can significantly promote the neovascularization and regenerative capacity of promoting tissue repair [ 21 , 22 ].…”

Section: Introductionmentioning

confidence: 99%

Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis

et al. 2021

View full text Add to dashboard Cite

Background Enhanced angiogenesis can promote diabetic wound healing. Mesenchymal stem cells (MSCs)-derived exosomes, which are cell-free therapeutics, are promising candidates for the treatment of diabetic wound healing. The present study aimed to investigate the effect of exosomes derived from MSCs pretreated with pioglitazone (PGZ-Exos) on diabetic wound healing. Results We isolated PGZ-Exos from the supernatants of pioglitazone-treated BMSCs and found that PGZ-Exos significantly promote the cell viability and proliferation of Human Umbilical Vein Vascular Endothelial Cells (HUVECs) injured by high glucose (HG). PGZ-Exos enhanced the biological functions of HUVECs, including migration, tube formation, wound repair and VEGF expression in vitro. In addition, PGZ-Exos promoted the protein expression of p-AKT, p-PI3K and p-eNOS and suppressed that of PTEN. LY294002 inhibited the biological function of HUVECs through inhibition of the PI3K/AKT/eNOS pathway. In vivo modeling in diabetic rat wounds showed that pioglitazone pretreatment enhanced the therapeutic efficacy of MSCs-derived exosomes and accelerated diabetic wound healing via enhanced angiogenesis. In addition, PGZ-Exos promoted collagen deposition, ECM remodeling and VEGF and CD31 expression, indicating adequate angiogenesis in diabetic wound healing. Conclusions PGZ-Exos accelerated diabetic wound healing by promoting the angiogenic function of HUVECs through activation of the PI3K/AKT/eNOS pathway. This offers a promising novel cell-free therapy for treating diabetic wound healing. Graphic abstract

show abstract

Therapeutic Applications of Mesenchymal Stem Cells in Idiopathic Pulmonary Fibrosis

Cited by 45 publications

References 124 publications

TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

TGF‑β1: Gentlemanly orchestrator in idiopathic pulmonary fibrosis (Review)

The Role of MSC in Wound Healing, Scarring and Regeneration

Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis

Contact Info

Product

Resources

About